Welcome to our dedicated page for EXELIXIS SEC filings (Ticker: EXEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Exelixis Inc. filings document regulatory disclosures for a Nasdaq-listed oncology company with common stock trading under EXEL. Recent 8-K reports furnish results of operations, financial-condition updates, corporate updates tied to the cabozantinib franchise and pipeline activity, and board-authorized common stock repurchase programs.
Proxy and governance filings cover director election matters, executive compensation, equity awards and shareholder voting materials. Other current reports document officer appointments, departures and related compensatory arrangements, connecting leadership changes to the company's research, development, legal and corporate functions.
PAPADOPOULOS STELIOS reported acquisition or exercise transactions in this Form 4 filing.
EXELIXIS, INC. director Stelios Papadopoulos received an equity award in the form of 8,367 restricted stock units, each equivalent to one share of common stock. The grant was made at no cash cost to him.
The RSUs are scheduled to vest 100% on May 27, 2027, provided he remains in continuous service through that date. After this award, his direct holdings reported in this filing total 1,197,595 shares of common stock, including the shares underlying the RSUs.
Heyman Tomas J. reported acquisition or exercise transactions in this Form 4 filing.
Exelixis director Tomas J. Heyman received a new equity award. He was granted 8,367 restricted stock units (RSUs) of Exelixis common stock on May 27, 2026 under the 2017 Equity Incentive Plan, with no cash paid per share.
Each RSU equals one share of common stock and will vest 100% on May 27, 2027, if he continues serving through that date. After this grant, Heyman holds 50,649 shares in total, including 17,455 shares that will be issued when previously granted RSUs vest.
Eckhardt Sue Gail reported acquisition or exercise transactions in this Form 4 filing.
EXELIXIS, INC. director Sue Gail Eckhardt received a grant of 8,367 restricted stock units on May 27, 2026 under the company’s 2017 Equity Incentive Plan. Each RSU represents one share of common stock and will vest in full on May 27, 2027 if she remains in continuous service. Following this award, she holds 25,891 shares of common stock, including 16,079 shares that will be issued upon vesting of outstanding RSUs.
Smith Julie reported acquisition or exercise transactions in this Form 4 filing.
EXELIXIS, INC. director Julie Smith reported an equity compensation grant of 8,367 restricted stock units on May 27, 2026. The award carries no purchase price and each unit is economically equivalent to one share of common stock.
The RSUs will vest in full on May 27, 2027, provided she remains in continuous service through that date. Following this grant, Smith is shown as holding 28,957 shares of common stock, including the shares that will be issued upon vesting of these RSUs.
Freire Maria C reported acquisition or exercise transactions in this Form 4 filing.
EXELIXIS, INC. director Maria C. Freire received a grant of 8,367 restricted stock units (RSUs) on May 27, 2026 under the Exelixis, Inc. 2017 Equity Incentive Plan. Each RSU equals one share of common stock and will vest 100% on May 27, 2027, subject to her continuous service. After this award, she directly holds 109,186 shares of common stock, including the shares underlying these RSUs.
Beckerle Mary C reported acquisition or exercise transactions in this Form 4 filing.
EXELIXIS, INC. director Mary C. Beckerle received a grant of 8,367 restricted stock units (RSUs), each equal to one share of common stock. The award was granted under the 2017 Equity Incentive Plan and will vest in full on May 27, 2027, subject to continuous service. Following this grant, she holds 25,891 shares and RSUs, including 16,079 shares issuable upon future RSU vesting.
Oliver Bob reported acquisition or exercise transactions in this Form 4 filing.
EXELIXIS, INC. director Oliver Bob received a grant of 8,367 shares of Common Stock in the form of restricted stock units as compensation. The RSUs were granted at no cash cost and will vest in full on May 27, 2027, if he remains in continuous service. After this award, he directly holds 29,487 shares, including 17,455 shares that will be issued upon vesting of existing RSUs.
WYSZOMIERSKI JACK L reported acquisition or exercise transactions in this Form 4 filing.
Exelixis, Inc. director Jack L. Wyszomierski received a grant of 8,367 restricted stock units, each equal to one share of common stock, under the 2017 Equity Incentive Plan. The RSUs vest in full on May 27, 2027, subject to continuous service, bringing his reported holdings to 288,309 shares.
POSTE GEORGE reported acquisition or exercise transactions in this Form 4 filing.
EXELIXIS, INC. director George Poste received a grant of 8,367 restricted stock units, each equal to one share of common stock and granted at no cost, under the company’s 2017 Equity Incentive Plan. The RSUs vest in full on May 27, 2027, subject to his continuous service. After this award, he directly beneficially owns 127,199 shares of common stock, including the unvested RSUs.
EXELIXIS, INC. director David Edward Johnson reported receiving an option grant covering 19,133 shares of common stock. The option has an exercise price of $50.03 per share, is exercisable immediately subject to repurchase provisions, and expires on May 26, 2033. It will vest in full on the first anniversary of the grant date, conditioned on Mr. Johnson’s continuous service. After this award, he holds options for 19,133 shares. Footnotes state the securities are deemed held for the benefit of Caligan Partners Master Fund LP and certain managed accounts of Caligan Partners LP, and may be transferred to those entities after vesting.